
Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round
getty Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases. The Series B was led by Korean venture capital firm DSC Investment, whose portfolio …